ReVeRa-201 (Completed) Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray for the Reduction of Ventricular Rate in Patients with Atrial Fibrillation Medicine Etripamil Population Arrhythmia Phase II Starting year 2022 Publicaties ReVeRa-201 Director of Study dr. M.E.W. Hemels (Cardioloog) Arnhem, Rijnstate Ziekenhuis
